✎ Contributed by Ty Griffin
- D-Wave and Japan Tobacco’s pharmaceutical division completed a proof-of-concept project aimed at speeding up and improving the design of small molecule pharmaceuticals.
- D-Wave’s annealing quantum computer was used to train large language models within Japan Tobacco’s AI framework.
- The quantum-hybrid application outperformed classical methods in generating valid and drug-like molecules.
- Japan Tobacco plans to further pursue Quantum AI in molecular design following these early results.
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the pharmaceutical division of Japan Tobacco Inc. (“JT”), have announced the successful completion of a proof-of-concept project applying quantum computing and artificial intelligence (“AI”) to drug discovery. The project demonstrated that a hybrid quantum-classical system outperformed classical methods in generating potential drug compounds (https://ibn.fm/5sTUn).
The project used D-Wave’s annealing quantum computer to enhance the training of large language models (“LLMs”) for chemical structure generation. LLMs, which are foundational to modern generative AI, were integrated into JT’s drug discovery process to explore chemical space and propose…
About D-Wave Quantum Inc.
D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. We are the world’s first commercial supplier of quantum computers, and the only company building both annealing and gate-model quantum computers. Our mission is to help customers realize the value of quantum, today. Our 5,000+ qubit AdvantageTM quantum computers, the world’s largest, are available on-premises or via the cloud, supported by 99.9% availability and uptime. More than 100 organizations trust D-Wave with their toughest computational challenges. With over 200 million problems submitted to our Advantage and Advantage2 systems to date, our customers apply our technology to address use cases spanning optimization, artificial intelligence, research and more. Learn more about realizing the value of quantum computing today and how we’re shaping the quantum-driven industrial and societal advancements of tomorrow: www.dwavequantum.com.
Forward Looking Statements
Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com
